The role of CD83 in the pathogenesis of immune thrombocytopenia.

IF 2 4区医学 Q3 HEMATOLOGY

Hematology Pub Date : 2024-12-01 Epub Date: 2024-07-12 DOI:10.1080/16078454.2024.2372482

Xiuli Wang, Qiyuan Zhou, Wen Yang, Hui Bi, Honghui Wang, Yacan Wang, Yadong Du, Lin Liu, Yuebo Liu, Liefen Yin, Jin Yao, Jingxing Yu, Wei Tao, Yongchun Zhou, Zeping Zhou

{"title":"The role of CD83 in the pathogenesis of immune thrombocytopenia.","authors":"Xiuli Wang, Qiyuan Zhou, Wen Yang, Hui Bi, Honghui Wang, Yacan Wang, Yadong Du, Lin Liu, Yuebo Liu, Liefen Yin, Jin Yao, Jingxing Yu, Wei Tao, Yongchun Zhou, Zeping Zhou","doi":"10.1080/16078454.2024.2372482","DOIUrl":null,"url":null,"abstract":"Background: CD83 are closely related to the pathogenesis of immune thrombocytopenia (ITP), but the exact mechanism remains unclear.Aim: To explore the relationship between CD83 and CD4+ T cell subsets and clarify the role of CD83 in the pathogenesis of ITP.Methods: RT-qPCR and Flow cytometry were used to illustrate CD83 expression. The downregulation and overexpression of DC-CD83 were co-cultured with CD4+ T cells to detect cell proliferation, co-cultured supernatant cytokines and Tregs expression.Results: The results indicate that the ITP patients showed higher expression of CD83 than the healthy controls. The proliferation of CD4+ T cells was inhibited by downregulation of DCs-CD83 but promoted by overexpression of DCs-CD83. siRNA-CD83 inhibited proinflammatory IFN-γ and IL-17 secretion while raising TGF-β, IL-10 concentrations. Overexpression of DCs-CD83 promoted Tregs expression.Conclusion: The Th1/Th2 and Th17/Tregs polarization were reversed via interfering DCs with siRNA-CD83. CD83 plays an important role in ITP pathogenesis, suggesting novel treatment for ITP patients.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/16078454.2024.2372482","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: CD83 are closely related to the pathogenesis of immune thrombocytopenia (ITP), but the exact mechanism remains unclear.

Aim: To explore the relationship between CD83 and CD4⁺ T cell subsets and clarify the role of CD83 in the pathogenesis of ITP.

Methods: RT-qPCR and Flow cytometry were used to illustrate CD83 expression. The downregulation and overexpression of DC-CD83 were co-cultured with CD4⁺ T cells to detect cell proliferation, co-cultured supernatant cytokines and Tregs expression.

Results: The results indicate that the ITP patients showed higher expression of CD83 than the healthy controls. The proliferation of CD4⁺ T cells was inhibited by downregulation of DCs-CD83 but promoted by overexpression of DCs-CD83. siRNA-CD83 inhibited proinflammatory IFN-γ and IL-17 secretion while raising TGF-β, IL-10 concentrations. Overexpression of DCs-CD83 promoted Tregs expression.

Conclusion: The Th1/Th2 and Th17/Tregs polarization were reversed via interfering DCs with siRNA-CD83. CD83 plays an important role in ITP pathogenesis, suggesting novel treatment for ITP patients.

查看原文本刊更多论文

CD83 在免疫性血小板减少症发病机制中的作用。

背景：目的：探讨CD83与CD4+ T细胞亚群的关系，明确CD83在ITP发病机制中的作用：方法：采用 RT-qPCR 和流式细胞术检测 CD83 的表达。方法：采用 RT-qPCR 和流式细胞仪检测 CD83 的表达，将下调和过表达的 DC-CD83 与 CD4+ T 细胞共培养，检测细胞增殖、共培养上清细胞因子和 Tregs 的表达：结果表明，ITP 患者的 CD83 表达高于健康对照组。siRNA-CD83 可抑制促炎性 IFN-γ 和 IL-17 的分泌，同时提高 TGF-β、IL-10 的浓度。DCs-CD83的过表达促进了Tregs的表达：结论：用 siRNA-CD83 干扰 DC 可逆转 Th1/Th2 和 Th17/Tregs 极化。CD83在ITP发病机制中起着重要作用，为ITP患者的治疗提供了新思路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematology 医学-血液学

CiteScore

2.60

自引率

5.30%

发文量

140

审稿时长

3 months

期刊介绍： Hematology is an international journal publishing original and review articles in the field of general hematology, including oncology, pathology, biology, clinical research and epidemiology. Of the fixed sections, annotations are accepted on any general or scientific field: technical annotations covering current laboratory practice in general hematology, blood transfusion and clinical trials, and current clinical practice reviews the consensus driven areas of care and management.